Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS.
Identifieur interne : 004F86 ( Main/Exploration ); précédent : 004F85; suivant : 004F87Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS.
Auteurs : Aftab A. Ansari [États-Unis] ; Ann E. Mayne ; Nattawat Onlamoon ; Kovit Pattanapanyasat ; Kazuyasu Mori ; Francois VillingerSource :
- Immunologic research [ 0257-277X ] ; 2004.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (génétique), Adjuvants immunologiques (usage thérapeutique), Animaux, Cytokines (génétique), Cytokines (usage thérapeutique), Humains, Interféron gamma (génétique), Interféron gamma (immunologie), Interleukine-12 (génétique), Interleukine-12 (immunologie), Interleukine-15 (génétique), Interleukine-15 (immunologie), Interleukine-2 (génétique), Interleukine-2 (immunologie), Macaca mulatta, Modèles animaux de maladie humaine, Protéines recombinantes (génétique), Protéines recombinantes (usage thérapeutique), Syndrome d'immunodéficience acquise (immunologie), Syndrome d'immunodéficience acquise du singe (immunologie), Syndrome d'immunodéficience acquise du singe (traitement médicamenteux), Virus de l'immunodéficience simienne (immunologie).
- MESH :
- génétique : Adjuvants immunologiques, Cytokines, Interféron gamma, Interleukine-12, Interleukine-15, Interleukine-2, Protéines recombinantes.
- immunologie : Interféron gamma, Interleukine-12, Interleukine-15, Interleukine-2, Syndrome d'immunodéficience acquise, Syndrome d'immunodéficience acquise du singe, Virus de l'immunodéficience simienne.
- traitement médicamenteux : Syndrome d'immunodéficience acquise du singe.
- usage thérapeutique : Adjuvants immunologiques, Cytokines, Protéines recombinantes.
- Animaux, Humains, Macaca mulatta, Modèles animaux de maladie humaine.
English descriptors
- KwdEn :
- Acquired Immunodeficiency Syndrome (immunology), Adjuvants, Immunologic (genetics), Adjuvants, Immunologic (therapeutic use), Animals, Cytokines (genetics), Cytokines (therapeutic use), Disease Models, Animal, Humans, Interferon-gamma (genetics), Interferon-gamma (immunology), Interleukin-12 (genetics), Interleukin-12 (immunology), Interleukin-15 (genetics), Interleukin-15 (immunology), Interleukin-2 (genetics), Interleukin-2 (immunology), Macaca mulatta, Recombinant Proteins (genetics), Recombinant Proteins (therapeutic use), Simian Acquired Immunodeficiency Syndrome (drug therapy), Simian Acquired Immunodeficiency Syndrome (immunology), Simian Immunodeficiency Virus (immunology).
- MESH :
- chemical , genetics : Adjuvants, Immunologic, Cytokines, Interferon-gamma, Interleukin-12, Interleukin-15, Interleukin-2, Recombinant Proteins.
- drug therapy : Simian Acquired Immunodeficiency Syndrome.
- immunology : Acquired Immunodeficiency Syndrome, Interferon-gamma, Interleukin-12, Interleukin-15, Interleukin-2, Simian Acquired Immunodeficiency Syndrome, Simian Immunodeficiency Virus.
- chemical , therapeutic use : Adjuvants, Immunologic, Cytokines, Recombinant Proteins.
- Animals, Disease Models, Animal, Humans, Macaca mulatta.
Abstract
Outbreaks of infectious diseases such as HIV and the much televised and attention-getting outbreaks of diseases such as Ebola, Hantaviruses, and the most recent outbreak of SARS have induced a significant new interest in the formulations and more importantly the science of vaccinology, which has previously to a large extent been conducted empirically. Our laboratory has focused on the use of recombinant nonhuman primate cytokines as adjunctive therapies for inducing antigen-specific immune responses in monkeys because most recombinant human cytokines appear to be immunogenic. This article provides a summary of our work with such cytokines, which includes attempts to define optimum dosing schedules that lead to optimal primary and lasting memory antigen-specific immune responses.
DOI: 10.1385/IR:29:1-3:001
PubMed: 15181266
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002D53
- to stream PubMed, to step Curation: 002D53
- to stream PubMed, to step Checkpoint: 002957
- to stream Ncbi, to step Merge: 000853
- to stream Ncbi, to step Curation: 000853
- to stream Ncbi, to step Checkpoint: 000853
- to stream Main, to step Merge: 005344
- to stream Main, to step Curation: 004F86
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS.</title><author><name sortKey="Ansari, Aftab A" sort="Ansari, Aftab A" uniqKey="Ansari A" first="Aftab A" last="Ansari">Aftab A. Ansari</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA. pathaaa@emory.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Mayne, Ann E" sort="Mayne, Ann E" uniqKey="Mayne A" first="Ann E" last="Mayne">Ann E. Mayne</name></author><author><name sortKey="Onlamoon, Nattawat" sort="Onlamoon, Nattawat" uniqKey="Onlamoon N" first="Nattawat" last="Onlamoon">Nattawat Onlamoon</name></author><author><name sortKey="Pattanapanyasat, Kovit" sort="Pattanapanyasat, Kovit" uniqKey="Pattanapanyasat K" first="Kovit" last="Pattanapanyasat">Kovit Pattanapanyasat</name></author><author><name sortKey="Mori, Kazuyasu" sort="Mori, Kazuyasu" uniqKey="Mori K" first="Kazuyasu" last="Mori">Kazuyasu Mori</name></author><author><name sortKey="Villinger, Francois" sort="Villinger, Francois" uniqKey="Villinger F" first="Francois" last="Villinger">Francois Villinger</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15181266</idno><idno type="pmid">15181266</idno><idno type="doi">10.1385/IR:29:1-3:001</idno><idno type="wicri:Area/PubMed/Corpus">002D53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002D53</idno><idno type="wicri:Area/PubMed/Curation">002D53</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002D53</idno><idno type="wicri:Area/PubMed/Checkpoint">002957</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002957</idno><idno type="wicri:Area/Ncbi/Merge">000853</idno><idno type="wicri:Area/Ncbi/Curation">000853</idno><idno type="wicri:Area/Ncbi/Checkpoint">000853</idno><idno type="wicri:doubleKey">0257-277X:2004:Ansari A:use:of:recombinant</idno><idno type="wicri:Area/Main/Merge">005344</idno><idno type="wicri:Area/Main/Curation">004F86</idno><idno type="wicri:Area/Main/Exploration">004F86</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS.</title><author><name sortKey="Ansari, Aftab A" sort="Ansari, Aftab A" uniqKey="Ansari A" first="Aftab A" last="Ansari">Aftab A. Ansari</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322, USA. pathaaa@emory.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pathology and Laboratory Medicine, Emory University School of Medicine, 1639 Pierce Drive, Atlanta, GA 30322</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Mayne, Ann E" sort="Mayne, Ann E" uniqKey="Mayne A" first="Ann E" last="Mayne">Ann E. Mayne</name></author><author><name sortKey="Onlamoon, Nattawat" sort="Onlamoon, Nattawat" uniqKey="Onlamoon N" first="Nattawat" last="Onlamoon">Nattawat Onlamoon</name></author><author><name sortKey="Pattanapanyasat, Kovit" sort="Pattanapanyasat, Kovit" uniqKey="Pattanapanyasat K" first="Kovit" last="Pattanapanyasat">Kovit Pattanapanyasat</name></author><author><name sortKey="Mori, Kazuyasu" sort="Mori, Kazuyasu" uniqKey="Mori K" first="Kazuyasu" last="Mori">Kazuyasu Mori</name></author><author><name sortKey="Villinger, Francois" sort="Villinger, Francois" uniqKey="Villinger F" first="Francois" last="Villinger">Francois Villinger</name></author></analytic><series><title level="j">Immunologic research</title><idno type="ISSN">0257-277X</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acquired Immunodeficiency Syndrome (immunology)</term><term>Adjuvants, Immunologic (genetics)</term><term>Adjuvants, Immunologic (therapeutic use)</term><term>Animals</term><term>Cytokines (genetics)</term><term>Cytokines (therapeutic use)</term><term>Disease Models, Animal</term><term>Humans</term><term>Interferon-gamma (genetics)</term><term>Interferon-gamma (immunology)</term><term>Interleukin-12 (genetics)</term><term>Interleukin-12 (immunology)</term><term>Interleukin-15 (genetics)</term><term>Interleukin-15 (immunology)</term><term>Interleukin-2 (genetics)</term><term>Interleukin-2 (immunology)</term><term>Macaca mulatta</term><term>Recombinant Proteins (genetics)</term><term>Recombinant Proteins (therapeutic use)</term><term>Simian Acquired Immunodeficiency Syndrome (drug therapy)</term><term>Simian Acquired Immunodeficiency Syndrome (immunology)</term><term>Simian Immunodeficiency Virus (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (génétique)</term><term>Adjuvants immunologiques (usage thérapeutique)</term><term>Animaux</term><term>Cytokines (génétique)</term><term>Cytokines (usage thérapeutique)</term><term>Humains</term><term>Interféron gamma (génétique)</term><term>Interféron gamma (immunologie)</term><term>Interleukine-12 (génétique)</term><term>Interleukine-12 (immunologie)</term><term>Interleukine-15 (génétique)</term><term>Interleukine-15 (immunologie)</term><term>Interleukine-2 (génétique)</term><term>Interleukine-2 (immunologie)</term><term>Macaca mulatta</term><term>Modèles animaux de maladie humaine</term><term>Protéines recombinantes (génétique)</term><term>Protéines recombinantes (usage thérapeutique)</term><term>Syndrome d'immunodéficience acquise (immunologie)</term><term>Syndrome d'immunodéficience acquise du singe (immunologie)</term><term>Syndrome d'immunodéficience acquise du singe (traitement médicamenteux)</term><term>Virus de l'immunodéficience simienne (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Cytokines</term><term>Interferon-gamma</term><term>Interleukin-12</term><term>Interleukin-15</term><term>Interleukin-2</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Simian Acquired Immunodeficiency Syndrome</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Cytokines</term><term>Interféron gamma</term><term>Interleukine-12</term><term>Interleukine-15</term><term>Interleukine-2</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Interféron gamma</term><term>Interleukine-12</term><term>Interleukine-15</term><term>Interleukine-2</term><term>Syndrome d'immunodéficience acquise</term><term>Syndrome d'immunodéficience acquise du singe</term><term>Virus de l'immunodéficience simienne</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>Interferon-gamma</term><term>Interleukin-12</term><term>Interleukin-15</term><term>Interleukin-2</term><term>Simian Acquired Immunodeficiency Syndrome</term><term>Simian Immunodeficiency Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Cytokines</term><term>Recombinant Proteins</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Syndrome d'immunodéficience acquise du singe</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Cytokines</term><term>Protéines recombinantes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Macaca mulatta</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Humains</term><term>Macaca mulatta</term><term>Modèles animaux de maladie humaine</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Outbreaks of infectious diseases such as HIV and the much televised and attention-getting outbreaks of diseases such as Ebola, Hantaviruses, and the most recent outbreak of SARS have induced a significant new interest in the formulations and more importantly the science of vaccinology, which has previously to a large extent been conducted empirically. Our laboratory has focused on the use of recombinant nonhuman primate cytokines as adjunctive therapies for inducing antigen-specific immune responses in monkeys because most recombinant human cytokines appear to be immunogenic. This article provides a summary of our work with such cytokines, which includes attempts to define optimum dosing schedules that lead to optimal primary and lasting memory antigen-specific immune responses.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Géorgie (États-Unis)</li></region></list><tree><noCountry><name sortKey="Mayne, Ann E" sort="Mayne, Ann E" uniqKey="Mayne A" first="Ann E" last="Mayne">Ann E. Mayne</name><name sortKey="Mori, Kazuyasu" sort="Mori, Kazuyasu" uniqKey="Mori K" first="Kazuyasu" last="Mori">Kazuyasu Mori</name><name sortKey="Onlamoon, Nattawat" sort="Onlamoon, Nattawat" uniqKey="Onlamoon N" first="Nattawat" last="Onlamoon">Nattawat Onlamoon</name><name sortKey="Pattanapanyasat, Kovit" sort="Pattanapanyasat, Kovit" uniqKey="Pattanapanyasat K" first="Kovit" last="Pattanapanyasat">Kovit Pattanapanyasat</name><name sortKey="Villinger, Francois" sort="Villinger, Francois" uniqKey="Villinger F" first="Francois" last="Villinger">Francois Villinger</name></noCountry><country name="États-Unis"><region name="Géorgie (États-Unis)"><name sortKey="Ansari, Aftab A" sort="Ansari, Aftab A" uniqKey="Ansari A" first="Aftab A" last="Ansari">Aftab A. Ansari</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F86 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004F86 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15181266
|texte= Use of recombinant cytokines for optimized induction of antiviral immunity against SIV in the nonhuman primate model of human AIDS.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15181266" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |